Core Viewpoint - Alibaba Health (00241) shares rose over 5%, reaching HKD 6.14, with a trading volume of HKD 14.52 billion, following an upgrade in revenue and profit growth guidance by Citi [1] Group 1: Financial Guidance - Citi raised Alibaba Health's revenue growth forecast for FY2026 to 10%-20% from the previous 5%-10% [1] - The adjusted net profit growth guidance was also increased to 20%-30% from 10%-20% [1] Group 2: Market Trends - The strong sales performance of original and innovative drugs, particularly GLP-1 medications, exceeded expectations [1] - The trend of prescription drug outflow is accelerating and appears sustainable, with Alibaba Health and JD Health being the primary beneficiaries [1] Group 3: Profit Forecast Adjustments - Based on the accelerated shift of original drugs from "in-hospital" to "out-of-hospital" markets, Citi adjusted Alibaba Health's net profit forecasts for FY2026 and FY2027 upwards by 8% and 12% respectively [1] - The target price for Alibaba Health was raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]

Core Viewpoint - The report from Citi highlights that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10%-20% and adjusted net profit growth guidance to 20%-30%, primarily driven by better-than-expected sales performance of innovative drugs, particularly GLP-1 medications [1] Company Summary - Alibaba Health's strong sales data, along with that of JD Health, confirms the acceleration and sustainability of the trend of prescription drug outflow [1] - The online platforms are identified as the biggest beneficiaries for innovative pharmaceutical companies in expanding new sales channels [1] - Citi has revised its adjusted net profit forecasts for Alibaba Health for fiscal years 2026 and 2027 upwards by 8% and 12% respectively [1] - The target price for Alibaba Health has been increased from HKD 4.8 to HKD 6.5, while maintaining an "Outperform" rating [1]

Core Viewpoint - Credit Suisse reports that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10% to 20% (previously 5% to 10%) and adjusted net profit growth guidance to 20% to 30% (previously 10% to 20%), primarily due to better-than-expected sales performance of original and innovative drugs, particularly GLP-1 drugs [1] Group 1 - Alibaba Health and JD Health's strong sales data confirm the accelerating and sustainable trend of prescription drug outflow [1] - The acceleration of original drug sales from hospitals to external markets has led to an 8% and 12% upward adjustment in Alibaba Health's adjusted net profit forecasts for fiscal years 2026 and 2027, respectively [1] - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]

Core Insights - Alibaba Health and LEO Pharma have announced a strategic partnership focused on digital health management and innovative drug accessibility, aiming to enhance patient care and streamline health services [1] - The collaboration marks a significant milestone in the integration of internet platforms with the pharmaceutical industry, emphasizing patient-centered digital health management [1] - Both companies aim to leverage their strengths to improve the management of chronic skin diseases, providing personalized and efficient health management solutions [1] Company Collaboration - The partnership will explore scientific management of post-diagnosis home care scenarios, enhancing the treatment adherence and accessibility of innovative medications [1] - Alibaba Health's CEO highlighted the integration of LEO's innovative drugs with their digital capabilities to facilitate easier treatment adherence for patients [1] - LEO Pharma's executive emphasized the transformative impact of digital technology on healthcare, aiming to provide comprehensive support for patients with skin diseases [1] Project Outcomes - Previous collaborations have yielded significant results, with a notable 30% increase in medication adherence among patients involved in the skin disease management project [2] - Patients participating in chronic disease community management experienced a 3.2 times increase in medication adherence, leading to improved disease control [2] - These outcomes demonstrate the effectiveness of digital interventions in managing chronic skin diseases and provide valuable insights for the industry [2]

Core Viewpoint - Alibaba Health and LEO Pharma have announced a strategic partnership to enhance digital health management and improve accessibility to innovative treatments for skin diseases [1][4]. Group 1: Strategic Partnership - The collaboration focuses on technology-driven medical innovation, comprehensive health management, and improving the accessibility of innovative drugs [1]. - Alibaba Health has a user base of 300 million and has partnered with thousands of pharmaceutical companies globally [3]. - LEO Pharma has been active in China, promoting awareness and standardized treatment for skin diseases like psoriasis and atopic dermatitis, helping over 65 million patients [3]. Group 2: Digital Health Management - The partnership aims to deepen the patient-centered digital health management model, integrating LEO's innovative drugs with Alibaba's digital capabilities [4]. - Previous joint projects have shown significant results, with patient medication adherence increasing by 30% and up to 3.2 times for those in chronic disease community management [3]. - The collaboration will continue to explore scientific management in post-diagnosis home settings, providing smarter, personalized, and efficient health management solutions [5].

Core Viewpoint - Alibaba Health and LEO Pharma have announced a strategic partnership to enhance digital health management and improve accessibility to innovative medications for patients [1][2]. Group 1: Strategic Collaboration - The collaboration will focus on new technology-driven medical innovations, comprehensive health management, and improving the accessibility of innovative drugs [1]. - Alibaba Health has established partnerships with thousands of pharmaceutical companies globally, leveraging its digital capabilities and online channel advantages [1]. - LEO Pharma has been dedicated to promoting scientific understanding and standardized treatment awareness for skin diseases in China, helping over 65 million patients through various initiatives [1]. Group 2: Project Outcomes - Previous collaborations have led to significant results in skin disease management projects, enhancing patient adherence to medication and self-management of diseases [1]. - Data indicates that patient adherence to medication improved by 30% compared to the previous year, with a 3.2 times increase in adherence among patients participating in chronic disease community management [1]. Group 3: Future Directions - The partnership aims to further explore scientific management in post-diagnosis home settings, providing more intelligent, personalized, and efficient health management solutions for patients [2].

Core Viewpoint - Alibaba Health (00241) has signed a 30-month lease agreement for a property in Hangzhou, enhancing its supply chain capabilities and operational efficiency [1] Group 1: Lease Agreement Details - The lease is between Alibaba Health's indirect wholly-owned subsidiary, Alibaba Health Pharmaceutical Chain, and Hangzhou Chuanfu, with a lease term starting from August 28, 2025 [1] - The leased property covers an area of approximately 87,000 square meters [1] Group 2: Strategic Importance - The property is located in the Alibaba Health Pharmaceutical Logistics Park in Tangjiadai Village, which is a key city in East China, specifically Hangzhou [1] - This facility will serve as a major warehouse for storing pharmaceuticals, medical devices, and various health-related products, significantly improving the company's supply chain capabilities and operational efficiency [1] - The company has already established operations in the area and built relationships with local suppliers [1]

Core Viewpoint - Alibaba Health (00241) has signed a 30-month lease agreement for a property in Hangzhou, enhancing its supply chain capabilities and operational efficiency [1] Group 1: Lease Agreement Details - The lease agreement is between Alibaba Health's indirect wholly-owned subsidiary, Alibaba Health Pharmaceutical Chain, and Hangzhou Chuanfu [1] - The leased property covers an area of approximately 87,000 square meters [1] - The lease term starts from August 28, 2025 [1] Group 2: Property Significance - The property is located in the Alibaba Health Logistics Park in Tangqiao Town, Linping District, Hangzhou, a key city for the company's operations in East China [1] - It will serve as a major warehouse facility for storing pharmaceuticals, medical devices, and various health-related products [1] - The establishment of this facility is expected to significantly improve the company's supply chain capabilities and operational efficiency [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） （股份代號：00241） 於2025年8月28日，本公司之間接全資附屬公司阿里健康醫藥連鎖（作為租戶）與杭 州傳賦（作為業主）就租賃該物業訂立租賃協議，租期自開始日期起計為期30個月， 據此，本集團將租賃該物業，租賃的樓面面積為約87,000平方米。 租賃協議 租賃協議之主要條款載列如下。 關連交易 — 租賃協議 租賃協議 於2025年8月28日，本公司之間接全資附屬公司阿里健康醫藥連鎖（作為租戶）與 杭州傳賦（作為業主）就租賃該物業訂立租賃協議，租期自開始日期起計為期30個 月，據此，本集團將租賃該物業，租賃的樓面面積為約87,000平方米。 上市規則之涵義 於本公告日期，阿里巴巴控股為本公司之最終控股股東。杭州傳賦為阿里巴巴控 股之間接全資附屬公司，故 ...

Market Overview - The Hang Seng Index closed at 25,201.76 points, down 1.27% [1] - The Hang Seng Tech Index closed at 5,697.53 points, down 1.47% [1] - The China Enterprises Index closed at 9,020.26 points, down 1.40% [1] - The Red Chip Index closed at 4,273.29 points, down 1.62% [1] Top Gainers - Nongfu Spring rose over 7% to 50.250 HKD [1][2] - NIO-SW increased over 4% to 51.700 HKD [1][2] - Shanghai Fudan and WanGuo Data-SW both rose over 1% [1][2] Top Losers - Beike-W fell over 6% to 47.200 HKD [1][2] - Naixue's Tea and Stone Pharmaceutical Group both dropped over 5% [1][2] - Li Ning, Alibaba Health, and Pop Mart fell over 4% [1][2] - JD Logistics, Zhou Hei Ya, and Mengniu Dairy declined over 3% [1][2] - Other notable declines include Zhou Dafu, Dongfang Zhenxuan, and Haidilao, all down over 2% [1][2]